



BIONEUTRA GLOBAL CORPORATION ANNOUNCES CEASE TRADE ORDER

Vancouver, British Columbia – (May 9, 2025) – BioNeutra Global Corporation (“BioNeutra” or the “Company”) (TSXV: BGA; OTC Pink: BGACF) announces an update regarding its continuous disclosure obligations and the issuance of a Cease Trade Order (CTO) by the British Columbia Securities Commission (“BCSC”) due to a delay in filing its audited annual financial statements and Management’s Discussion and Analysis (MD&A) for the fiscal year ended December 31, 2024.

The delay in filing arises from unforeseen complexities in the audit process, and an expanded audit scope resulting in significant additional procedures.

BioNeutra remains fully committed to resolving this matter expediently and is undertaking all necessary measures to complete the audit and related filings after which the Company intends to apply for a revocation of the CTO as early as possible.

“Our priority is to finalize the audit and fulfill all disclosure requirements as soon as possible,” said **Dr. Jianhua Zhu, President and CEO of BioNeutra**. “We understand the importance of timely reporting and we appreciate our shareholders’ patience. We remain focused on full compliance and on creating long-term value for our investors.”

About BioNeutra

BioNeutra is an award-winning, sector-leading Canadian company in the business of research and development, production and commercialization of ingredients for nutraceutical, functional and mainstream foods and beverages with a focus on its lead product - VitaFiber® IMO.

VitaFiber® IMO is made using a patented process that naturally transforms starch molecules from agricultural crops such as pea or tapioca into healthy, functional molecules. The VitaFiber manufacturing process is based upon a natural enzymatic conversion of the molecules without any chemical modification involved making VitaFiber® IMO a natural food and beverage ingredient. VitaFiber® IMO is also non-

1101-1030 West Georgia Street, Vancouver
British Columbia, Canada, V6E 2Y3
Tel: (780) 466-1481 Fax: (780) 485-1490
E-mail: info@bioneutra.ca www.bioneutra.ca



GMO, vegan friendly, gluten-free, Kosher and Halal certified and available as certified organic. VitaFiber® IMO has been approved for sale by the world's top three health regulatory bodies – GRAS approved by the US Food & Drug Administration; the European Food Safety Authority and Health Canada (approved as a novel food ingredient and dietary fiber). VitaFiber® IMO is a naturally sweet, low calorie alternative to sugar and is a natural source of dietary fiber and prebiotic for human digestive health. It is also helpful with weight management.

The Company's customers include a mix of small and medium businesses as well as a number of high-profile food and beverage manufacturers on four continents.

Further information about BioNeutra is available on the Company's website at www.bioneutra.ca and the SEDAR website at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on BioNeutra, please contact:

Dr. Jianhua Zhu
President and Chief Executive Officer
Tel: (780) 466-1481 (Ext. 132)
Email: jianhua.zhu@bioneutra.ca

1101-1030 West Georgia Street, Vancouver
British Columbia, Canada, V6E 2Y3
Tel: (780) 466-1481 Fax: (780) 485-1490
E-mail: info@bioneutra.ca www.bioneutra.ca



Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of BioNeutra. Forward-looking information is based on certain key expectations and assumptions made by the management of BioNeutra. Although BioNeutra believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioNeutra can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioNeutra disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

1101-1030 West Georgia Street, Vancouver
British Columbia, Canada, V6E 2Y3
Tel: (780) 466-1481 Fax: (780) 485-1490
E-mail: info@bioneutra.ca www.bioneutra.ca